Long-term cognitive function change among breast cancer survivors
- 530 Downloads
Cognitive decline is a common health problem among breast cancer patients and understanding trajectories of cognitive change following among breast cancer survivors is an important public health goal. We conducted a longitudinal study to investigate the cognitive function changes from 18 month to 3 years after breast cancer diagnosis among participants of the Shanghai Breast cancer survivor study, a population-based cohort study of breast cancer survivors. In our study, we completed cognitive function evaluation for 1,300 breast cancer survivors at the 18th month’s survey and 1,059 at 36th month’s survey, respectively, using a battery of cognitive function measurements. We found the scores in attention and executive function, immediate memory and delayed memory significantly improved from 18 to 36 months after breast cancer diagnosis. The improvements appeared in breast cancer survivors receiving treatments (i.e., surgery, radiotherapy, tamoxifen, or chemotherapy combined with or without tamoxifen), but not in those who received neither chemotherapy nor tamoxifen treatment. The results indicate that cognitive functions, particularly immediate verbal episodic memory, and delayed memory significantly improved among breast cancer survivors from 18 to 36 months after cancer diagnosis. In general, comorbidity was inversely associated with the improvements.
KeywordsBreast cancer Cognitive function Prognosis Survival
The authors thank the breast cancer patients who participated in the study and the research staff of the Shanghai Breast Cancer Survivor Study for their dedication and contributions to the study. The parent study was supported by grants from the US Department of Defense Breast Cancer Research Program (Grant DAMD 17-02-1-0607), the National Cancer Institute (Grant R01 CA118229) and The Shanghai Public Health Talented Professional Overseas Training Program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
Conflict of interest
The authors indicated no potential conflicts of interest.
- 1.Boyle P, Levin B (eds) (2008) World Cancer Report. International Agency for Research on Cancer, LyonGoogle Scholar
- 2.Brenner H (2002) Long-term survival rates of cancer survivors achieved by the end of the 20th century: a period analysis. Lancet 360(1131–1135):2002Google Scholar
- 7.Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, Bishop H, Hodson N, Mitra S, Sadler G et al (2006) A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828–834PubMedCentralPubMedCrossRefGoogle Scholar
- 16.Conroy SK, McDonald BC, Smith DJ, Moser LR, West JD, Kamendulis LM, Klaunig JE, Champion VL, Unverzagt FW, Saykin AJ (2013) Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Res Treat 137:493–502PubMedCentralPubMedCrossRefGoogle Scholar
- 19.Mar Helen G, Fan Nadine Houédé-Tchen, Yi Qi-Long, Chemerynsky I, Downie FP, Sabate K, Tannock IF (2005) Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23:8025–8032CrossRefGoogle Scholar
- 29.Klepin H, Mohile S, Hurria A (2009) Geriatric assessment in older survivors with breast cancer. J Natl Compr Cancer Netw 7:226–236Google Scholar
- 33.Vodermaier A (2009) Breast cancer treatment and cognitive function: the current state of evidence, underlying mechanisms and potential treatments. Womens Health 5:503–516Google Scholar
- 34.Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28:4434–4440PubMedCentralPubMedCrossRefGoogle Scholar